Watch XLO. Know when insiders buy.
One email the day a filing lands. Free.
XLO
Xilio Therapeutics, Inc.
9.01
+0.10 +1.12%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
52
WATCH · shorts 52
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $52.1MP/E —DIV YIELD —FCF YIELD -117.60%REV TTM $64.1M +327.3%NET INCOME −$21.8MNET CASH —52W 7.14 – 11.90SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $18.7M | +131.2% | — | −$3.5M | −$6.4M | — | -0.33 | −$18.8M | $19K | −$18.8M | Aug 12 |
| Q1 2026 · Mar 31 | $12.6M | +331.7% | — | −$14.1M | −$9.5M | — | -0.58 | −$22.3M | $556K | −$22.9M | May 12 |
| Q4 2025 · Dec 31derived | $13.7M | +693.9% | — | −$11.8M | $10.4M | — | -3.76 | −$2M | $95K | −$2.1M | Mar 23 |
| Q3 2025 · Sep 30 | $19.1M | +742.5% | — | −$1.9M | −$16.3M | — | -0.11 | −$17.5M | $0 | −$17.5M | Nov 13 |
| Q2 2025 · Jun 30 | $8.1M | +243.0% | — | −$14.4M | −$15.8M | — | -2.30 | −$14.5M | $401K | −$14.9M | Aug 12 |
| Q1 2025 · Mar 31 | $2.9M | — | — | −$13.9M | −$13.3M | — | -2.49 | $29M | $22K | $29M | May 12 |
| Q4 2024 · Dec 31derived | $1.7M | — | — | −$13.6M | −$13.1M | — | -14.33 | −$14.2M | $6K | −$14.2M | Mar 23 |
| Q3 2024 · Sep 30 | $2.3M | — | — | −$14.8M | −$14M | — | -0.22 | −$13.7M | $9K | −$13.7M | Nov 13 |
| Q2 2024 · Jun 30 | $2.4M | — | — | −$14.7M | −$13.9M | — | -0.24 | $20M | — | — | Aug 14 |
| Q1 2024 · Mar 31 | — | — | — | −$17.5M | −$17.2M | — | -0.62 | −$10.5M | — | — | May 8 |
| Q4 2023 · Dec 31derived | — | — | — | −$18.1M | −$17.7M | — | -0.64 | −$13.4M | $0 | −$13.4M | Mar 11 |
| Q3 2023 · Sep 30 | — | — | — | −$17.4M | −$16.7M | — | -0.61 | −$13.4M | $0 | −$13.4M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $43.8M | — | −$42M | −$35M | -80.1% | -4.19 | −$5M | $518K | −$5.5M | — | — |
| FY2024 · to Dec 31 | $6.3M | — | −$60.6M | −$58.2M | -918.0% | -15.24 | −$18.4M | $36K | −$18.4M | — | — |
| FY2023 · to Dec 31 | — | — | −$79.1M | −$76.4M | — | -2.78 | −$68.6M | $486K | −$69.1M | — | — |
| FY2022 · to Dec 31 | — | — | −$89.1M | −$88.2M | — | -3.22 | −$75.7M | $1.9M | −$77.6M | — | — |
| FY2021 · to Dec 31 | — | — | −$75M | −$75.8M | — | -13.52 | −$80.8M | $1.1M | −$81.9M | — | — |
| FY2020 · to Dec 31 | — | — | −$54.6M | −$55.2M | — | -105.42 | −$36.1M | $2.2M | −$38.3M | — | — |
Every number comes from Xilio Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.